Your browser is no longer supported. Please, upgrade your browser.
Settings
NXTC NextCure, Inc. daily Stock Chart
NXTC [NASD]
NextCure, Inc.
Index- P/E- EPS (ttm)-1.33 Insider Own- Shs Outstand27.24M Perf Week3.28%
Market Cap1.41B Forward P/E- EPS next Y-1.69 Insider Trans- Shs Float23.76M Perf Month37.54%
Income-29.70M PEG- EPS next Q-0.43 Inst Own41.60% Short Float2.63% Perf Quarter39.83%
Sales4.30M P/S328.91 EPS this Y-47.40% Inst Trans4.70% Short Ratio1.27 Perf Half Y243.39%
Book/sh7.50 P/B6.92 EPS next Y21.40% ROA- Target Price72.20 Perf Year-
Cash/sh6.75 P/C7.69 EPS next 5Y40.10% ROE- 52W Range13.86 - 109.00 Perf YTD160.90%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-52.37% Beta-
Dividend %- Quick Ratio15.00 Sales past 5Y- Gross Margin- 52W Low274.60% ATR8.06
Employees44 Current Ratio15.00 Sales Q/Q- Oper. Margin- RSI (14)58.24 Volatility8.29% 8.39%
OptionableYes Debt/Eq0.03 EPS Q/Q-42.50% Profit Margin- Rel Volume0.50 Prev Close51.24
ShortableNo LT Debt/Eq0.02 EarningsNov 11 Payout- Avg Volume491.60K Price51.92
Recom1.60 SMA2018.64% SMA5034.17% SMA20081.24% Volume244,219 Change1.33%
Dec-05-19Initiated Needham Buy
Nov-26-19Initiated BTIG Research Buy $61
Jul-09-19Initiated BofA/Merrill Buy $25
Jun-03-19Initiated Piper Jaffray Overweight $26
Jun-03-19Initiated Morgan Stanley Overweight $25
Nov-26-19 08:05AM  NextCure to Present at Piper Jaffray 31st Annual Healthcare Conference GlobeNewswire
Nov-19-19 04:05PM  NextCure Announces Closing of Public Offering GlobeNewswire
Nov-15-19 10:09AM  The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval Benzinga -6.49%
Nov-14-19 10:10PM  NextCure Announces Pricing of Public Offering of Common Stock GlobeNewswire
Nov-12-19 04:18PM  NextCure Announces Proposed Public Offering of Common Stock GlobeNewswire
03:25PM  Analyst Trims NextCure Price Target Following SITC Presentation, Still Sees Big Upside Benzinga
08:05AM  NextCure Reports Third Quarter 2019 Financial Results GlobeNewswire
Nov-11-19 01:37PM  NextCure Stock Collapses After New Cancer Drug Data Barrons.com -52.93%
10:53AM  These Are The Winners Of The Inaugural WeTrader Paper Trading Competition Benzinga
Nov-09-19 05:05PM  NextCure Presents Updated Clinical Data from NC318 Phase 1/2 Clinical Trial at the 34th Annual Meeting of Society for Immunotherapy of Cancer (SITC) and Announces Initiation of Phase 2 Portion of the Trial GlobeNewswire
Nov-04-19 08:05AM  NextCure to Host and Webcast Event at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting GlobeNewswire
Nov-01-19 04:24PM  WeWork IPO was a Failure These 2 IPO Stocks are Surging InvestorPlace +9.40%
Oct-02-19 07:30AM  NextCure Announces Promotion of Timothy Mayer, Ph.D., to Chief Operating Officer GlobeNewswire
Oct-01-19 06:20PM  NextCure to Present Clinical Data from NC318 Phase 1/2 Clinical Trial at 34th Annual Meeting of SITC GlobeNewswire
Sep-03-19 04:05PM  NextCure to Present at Morgan Stanley 17th Annual Global Healthcare Conference GlobeNewswire +6.02%
Aug-12-19 04:05PM  NextCure Reports Second Quarter 2019 Financial Results GlobeNewswire
Aug-08-19 06:02AM  What Kind Of Shareholder Owns Most NextCure, Inc. (NASDAQ:NXTC) Stock? Simply Wall St. -6.68%
Jul-18-19 11:20AM  2 Small-Cap Biotech IPOs You Should Know About Motley Fool +6.36%
Jun-10-19 04:05PM  NextCure Reports First Quarter 2019 Financial Results GlobeNewswire -5.67%
May-08-19 08:46PM  NextCure Announces Pricing of Initial Public Offering of Common Stock GlobeNewswire
May-04-19 05:25PM  IPO Outlook For The Week: Uber (And 11 Others) Benzinga
NextCure, Inc., a biopharmaceutical company, engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase I/II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, is a novel immunomedicine designed to block immune suppression for the treatment of ovarian cancer, non-small cell lung cancer, and renal cancer. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules that targets a novel member of the B7-family of immunomodulatory proteins; and an antibody in preclinical development targeting an immune modulator that is expressed in inflamed tissue and the tumor microenvironment in various tumor types. NextCure, Inc. has a license agreement with Yale University; and a research and development collaboration with Eli Lilly and Company. The company was founded in 2015 and is based in Beltsville, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sofinnova Venture Partners IX,10% OwnerNov 15Buy36.75150,0005,512,5002,671,856Nov 19 09:47 PM